Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Quest for Outpatient Mastectomy in COVID-19 Era: Barriers and Facilitators.

The breast journal·2022
Same author

2-year outcomes of phased radiofrequency ablation for atrial fibrillation with the second-generation PVAC Gold ablation catheter.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing·2022
Same author

Acute success and safety of the second-generation PVAC GOLD phased RF ablation catheter for atrial fibrillation.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing·2020
Same author

Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study.

BJOG : an international journal of obstetrics and gynaecology·2018
Same author

Longitudinal evaluation of diffusion tensor imaging and cognition in systemic lupus erythematosus.

Lupus·2018
Same author

McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome.

Journal of thrombosis and haemostasis : JTH·2018

Related Experiment Video

Updated: Jun 4, 2026

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Antiphospholipid Syndrome Clinical Research Task Force report.

D Erkan1, R Derksen, R Levy

  • 1Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY, USA. erkand@hss.edu

Lupus
|February 10, 2011
PubMed
Summary

The Antiphospholipid Syndrome (APS) Clinical Research Task Force identified key issues in APS research, including inconsistent aPL detection methods and heterogeneous patient groups. They emphasized the need for standardized testing and prospective studies to improve clinical trial design. An international meeting in 2010 used the FINER criteria to develop research questions. The task force concluded that multicenter trials are essential for evidence-based APS management recommendations.

Keywords:
Antiphospholipid Syndrome researchaPL antibody detectionclinical trial designautoimmune disease management

Frequently Asked Questions

More Related Videos

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Related Experiment Videos

Last Updated: Jun 4, 2026

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Area of Science:

  • Autoimmune disease clinical research
  • Thrombosis and pregnancy outcome studies
  • Antibody detection methodology

Background:

Current APS clinical research lacks consistency in aPL testing and patient selection. Prior studies have shown that aPL-positive patients present with varied clinical risks. No prior work had resolved how to standardize aPL detection methods. This gap motivated the formation of the APS Clinical Research Task Force. The task force aimed to address limitations in APS research design. Existing studies often include patients with single aPL results or low titers. Retrospective study designs limit the ability to quantify clinical risks. A lack of understanding of aPL-mediated mechanisms further hinders study quality.

Purpose Of The Study:

The task force aimed to evaluate APS clinical research limitations and develop guidelines for improvement. Researchers sought to prioritize ideas for multicenter trials. They focused on standardizing aPL detection and patient inclusion criteria. The goal was to improve the quality of APS research and management recommendations. They identified five major issues affecting APS research. These issues include non-standardized aPL testing and heterogeneous patient groups. The task force also aimed to incorporate risk stratification in studies. Their work aimed to guide future clinical trial design.

Main Methods:

The task force used a systematic working algorithm to identify APS research limitations. They reviewed clinical and basic research studies for methodological gaps. Researchers evaluated aPL detection methods and patient inclusion criteria. They analyzed how aPL profiles affect clinical event risks. The task force considered the heterogeneity of APS manifestations. They examined the use of single or low-titer aPL results in studies. Retrospective study designs were assessed for their limitations. The task force prioritized ideas for prospective multicenter trials.

Main Results:

The task force identified five major issues in APS clinical research. First, aPL detection relies on non-standardized tests. Second, APS studies include patients with different aPL profiles. Third, risk stratification is rarely incorporated in research. Fourth, most studies are retrospective and population-based. Fifth, mechanisms of aPL-mediated events are poorly understood. The task force recommended international collaboration for clinical trials. A meeting in November 2010 used FINER criteria to formulate research questions.

Conclusions:

The task force concluded that APS research requires standardized aPL detection. They emphasized the need for consistent patient inclusion criteria. Risk stratification should be incorporated in future studies. Prospective, multicenter trials are necessary for evidence-based recommendations. The task force proposed an international collaborative approach. They highlighted the importance of understanding aPL-mediated mechanisms. Their findings suggest that current study designs limit clinical relevance. The task force aims to improve APS research quality through collaboration.

APS research lacks standardized aPL detection and includes heterogeneous patient groups. Risk stratification is rarely used, and most studies are retrospective.

aPL detection relies on partially or non-standardized tests, leading to inconsistent patient inclusion and clinical risk assessment.

The FINER criteria help formulate feasible, interesting, novel, ethical, and relevant research questions for APS trials.

APS patients have diverse aPL profiles and clinical manifestations, which can confound study results and limit generalizability.

The task force recommends international collaboration for well-designed, prospective multicenter trials with standardized aPL detection.

Prospective studies allow for better risk stratification and quantification, improving the quality of evidence for APS management.